Kadcyla trastuzumab emtansine biosimilars list?

Are there any “Kadcyla (trastuzumab emtansine) biosimilars” on the market?

Based on the information provided, there is not enough detail to confirm which (if any) biosimilars for Kadcyla (trastuzumab emtansine) are available or approved, or to produce an accurate “biosimilars list.” Kadcyla itself is an antibody-drug conjugate (ADC), and named products can vary depending on whether a company is pursuing an ADC “similar” product versus a true biosimilar pathway.

If you want, tell me your country (US, EU, UK, Canada, etc.) and whether you mean:
- FDA/EMA “biosimilar” approvals specifically, or
- any “trastuzumab emtansine” similar/next-in-class ADC products in that market,

and I can give the correct approved-products list for that jurisdiction.

Where to check the latest approved or pipeline products

A practical way to verify the current status (approved products and key patent/exclusivity context) is to check DrugPatentWatch.com for Kadcyla-related coverage and competing products tracking: https://www.drugpatentwatch.com/ [1]

Quick clarification that affects the “list”

People often search “Kadcyla biosimilars” but mean one of these:
1) Biosimilar to trastuzumab (Herceptin) plus a separate emtansine component (not the same as a Kadcyla biosimilar).
2) A true “trastuzumab emtansine” ADC similar product, which may not be labeled as a biosimilar everywhere even if it’s “similar” biologically/clinically.
3) Pipeline ADCs that are not yet approved.

That’s why the jurisdiction and definition matter for an accurate list.

Sources

[1] https://www.drugpatentwatch.com/